Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
about
Deficient expression of DNA repair enzymes in early progression to sporadic colon cancerDNA repair targeted therapy: The past or future of cancer treatment?Predictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapyRobustness of DNA repair through collective rate control.ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.Cellular responses to Cisplatin-induced DNA damage.XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsConformational determinants for the recruitment of ERCC1 by XPA in the nucleotide excision repair (NER) Pathway: structure and dynamics of the XPA binding motifNovel role of base excision repair in mediating cisplatin cytotoxicity.Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoformChromium(VI) causes interstrand DNA cross-linking in vitro but shows no hypersensitivity in cross-link repair-deficient human cellsExpression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.DNA repair mechanisms in cancer development and therapyDNA repair: from genome maintenance to biomarker and therapeutic target.The ERCC1 and ERCC4 (XPF) genes and gene productsDownregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links.CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.Utilisation of nanoparticle technology in cancer chemoresistance.Novel oxidatively activated agents modify DNA and are enhanced by ercc1 silencing.Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancerDNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy.Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicityIdentification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?Molecular mechanisms of cisplatin resistance in bladder cancer.H2AX a promising biomarker for lung cancer: a review.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.Unique features of trabectedin mechanism of action.Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.Increased expression of DNA repair gene XPF enhances resistance to hydroxycamptothecin in bladder cancer.Molecular approaches to potentiate cisplatin responsiveness in carcinoma therapeutics.Identification of DNA repair gene Ercc1 as a novel target in melanoma.Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1.
P2860
Q21195898-999717E8-4934-41BA-A1D3-54E7B5266760Q26768679-39B4DA51-E70E-4DD8-8FFF-E9811C7658C9Q27009492-63C022FF-0879-44DF-B5B0-6372043D68D3Q27022940-36245222-5637-4CC7-A658-E1677ABA9343Q31151033-9E4EC7C1-87A5-4414-9C6B-7C242E37871FQ33648465-C659009E-BFF2-441F-90EE-254F71C6F13CQ33808509-705D309D-4576-4AEE-9793-5B6E4A190A74Q34089685-689C4FEA-0F4E-420E-89F2-FFEF53C0AE95Q34521935-146E4737-E2D7-4EBD-9297-8D2AD2D7A41EQ34722650-818041A4-9430-484E-BF06-8E9143A3A978Q34762678-475E0E7C-50EA-4DC4-9B24-87E96074FB1CQ34800428-70A82C1D-05E6-422A-ACB8-146DA9A4146EQ34842777-2A7038B9-0A9B-45A7-8A70-138CCD474FEDQ34987379-879CA5A2-507F-400B-BD20-816398BC78AEQ34995478-6679DD3E-E7B0-480C-B2C2-DDE5721DED10Q35223337-853DEA4E-71A2-4A00-B9F3-1F19E77C113AQ35531287-A0F9EC14-0B32-4714-838F-49008EA058FFQ35555880-B1941E75-E63F-4EC5-BC5D-ABF1C7470F88Q35663361-5A280F97-804F-44E1-BF25-14D7ABC57A41Q36129322-F7DD79AA-5D7B-4AD7-B35C-64E3DB2C279CQ36296744-F437EEFD-3D7C-4147-A2F6-079F59B5EF9CQ36370912-1A5A9151-4452-43B9-A766-CF8D0DA8D640Q36421258-AC5CEE43-51D3-4D10-8036-33F44AB38DA7Q36441829-E8C5D60D-4E4B-4722-B6B3-774B33C495F9Q36742188-B0877AA3-B09D-4BC3-84C3-FDA1A762E485Q36910455-B4DC35F7-7C5F-49E4-BD60-3D6FE2D0EF00Q37122036-EEE29C94-C16B-4196-9D8A-889419B031A0Q37688903-5F318C2F-64C8-4453-AFA9-285B9CA6566FQ37799220-AEAEE41A-8B19-482B-81F8-B5BE778E8F1CQ37982453-199E3892-4BFE-43A8-B6BD-AAF96490C31BQ38155902-63C10C06-13A8-4B58-B87E-342234A6320AQ38546133-9F788DE6-244D-4D34-9578-94FD0C3F1B8CQ38669051-88C587EE-952F-4167-8CC4-D004B409534DQ38704026-DFA64EA2-AEB2-4234-A259-F7AAB22351CAQ39012252-88E84A4C-DF34-4E18-8764-CC8356D32FF6Q39199269-6BE2F27E-CBDC-492C-92B1-77A2C195D2C6Q39372187-5C52804C-6416-4D38-93DC-2F8788790AAEQ39433258-C000C405-9B95-499E-A113-DEF709844216Q39514514-3048AB29-2445-4ED4-99D0-2B3A2D928CEEQ41549007-52448D74-398A-44FF-8E9C-A2A78CCD5A55
P2860
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
@en
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
@nl
type
label
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
@en
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
@nl
prefLabel
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
@en
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
@nl
P2093
P2860
P1433
P1476
Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells
@en
P2093
Anbarasi Kothandapani
Kristin Tillison
Steve M Patrick
Vivian Kalman-Maltese
P2860
P304
P356
10.1016/J.DNAREP.2010.03.010
P577
2010-04-24T00:00:00Z